The pre-mRNA splicing factor SF3b1 exhibits recurrent mutations among hematologic malignancies and cancers, and consequently is a major therapeutic target of clinically-advanced spliceosome inhibitors. In this review, we highlight and rigorously analyze emerging views of SF3b1 conformational transitions, including the human SF3b particle either in isolation or bound to spliceosome inhibitors, and human or yeast spliceosome assemblies. Among spliceosome states characterized to date, an SF3b1 α-helical superhelix significantly closes to surround a U2 small nuclear RNA duplex with the pre-mRNA branch point sequence. The SF3b1 torus is locally unwound at an active site adenosine, whereas protein cofactors appear to stabilize overall closure in the spliceosome. Network analyses demonstrates that the natural SF3b1 dynamics mimic its conformational change in the spliceosome, raising the possibility of conformational selection underpinning spliceosome assembly. These dynamic SF3b1 conformations have consequences for gatekeeping of spliceosome assembly and therapeutic targeting of its cancer-associated dysfunction.
extrahelical branchsite adenosine packs between the PHF5a subunit and the central SF3b1/Hsh155 repeats, including hydrophobic/aromatic stacking and phosphodiester salt bridges. In contrast with the well-defined SF3b1-bound BPS, structures of isolated U2 -BPS-containing RNA duplexes are dynamic in the absence of protein chaperones [17] [18] [19] , suggesting that SF3b1 functions to promote the bulged branchsite conformation. Several spliceosome structures (human PDB ID's 6QX9, 6AH0, 6AHD, 5Z56, 5Z57, 5Z58; yeast PDB ID's 5ZWM, 5ZWO, 5LQW, 5GM6) report intron sequences downstream of the BPS traversing the mutation-prone HEAT repeats of SF3b1 (or corresponding sites of Hsh155) ( Fig. 3B ). Structure-guided alanine-scanning mutagenesis has shown that the SF3b1/Hsh155 contacts with this intronic region are important for yeast growth, whereas most BPS -BSRR contacts are dispensable with the exception of a K1149/K818 side chain interaction near the branch point [20] .
Additional protein subunits assemble on the SF3b1/Hsh155 scaffold in the context of the spliceosome (Fig. 2C) . A few α-helices of the SF3b2/Cus1 subunit consistently bind the exterior of the SF3b1 torus and appear to stabilize SF3a and SF3b4-mediated contacts with the U2 snRNA. In the activated B ACT spliceosome [15, 21, 22] , massive rearrangements shift a major spliceosomal protein, Prp8 close to SF3b1/ Hsh155, where it appears to contact α-helical repeats preceding the branchsite pocket. A Bud13 subunit of the pre-mRNA retention and splicing (RES) bridges Prp8 and the RBMX2/Snu17 RES subunit, which in turn sandwiches the intron RNA against the cancer-affected SF3b1 repeats. In human spliceosomes [21] [22] [23] [24] , a globular SF3b6 subunit (also called p14a) binds N-terminal to the SF3b1 α-helical repeat domain, further interactions among SF3b1, the RES complex and Prp8 following spliceosome rearrangements to the B ACT stage [21] . Transient, early-stage splicing factors such as U2AF and its paralogues are thought to bind "U2AF Ligand Motifs" (ULM) of SF3b1 immediately adjacent its SF3b6-binding site [25] , expanding a role for SF3b1 as a transient hub for multiple splicing factor interactions.
RNA helicases mediate an SF3b-dependent checkpoint for spliceosome activation, including DDX46/Prp5 for SF3b integration in the Acomplex [7] , snRNP200/Brr2 for dissociation of the U4 snRNP and snRNP-specific proteins at the B-to-B ACT transition [26, 27] , and DHX16/Prp2 for release SF3b at the time of the first transesterification reaction in the B* complex [8] [9] [10] . Although DDX46/Prp5 has yet to be resolved in spliceosome structures, in vitro interaction and yeast genetic experiments indicate that this helicase binds SF3b1/Hsh155 and thereby displaces a Tat-SF1/Cus2-mediated checkpoint for spliceosome assembly [28] [29] [30] . In the B ACT complex, snRNP200/Brr2 packs against the SF3b3 subunit near SF3b1, and there bridges an additional interface between the SF3b particle and the activated Prp8 conformation [15, 21] . DHX16/Prp2 also becomes evident in the B ACT complex, in [20, 28, 29, 31] , thereby regulating SF3b association and release during spliceosome assembly.
SF3b1 conformational changes following spliceosome integration

Overall SF3b1 conformation in the isolated particle compared to the spliceosome
In the isolated SF3b particle, SF3b1 is in an "open" conformation with the N-and C-terminal α-helical repeats separated at a distance that is incompatible with simultaneous binding to both U2 snRNA and BPS strands [14] . In the spliceosome, the SF3b1 superhelix closes by~23°to surround the BPS -U2 snRNA duplex (e.g. Fig. 4 , Supplementary Movie S1, RMSD is 6.0 Å among 735 matching Cα atoms of PDB ID's 5IFE and 6FF4). Closure in the spliceosome significantly decreases the size of the internal cavity within the SF3b1 torus (by nearly 25,000 Å 3 calculated using CASTp [32] , Fig. 5 ). This magnitude of the conformational change remains similar regardless of the homolog (Saccharomyces cerevisiae compared to human) or the stage of spliceosome assembly (RMSD's in Table 1 ), with the caveat that locally lower resolutions of SF3b1-containing regions could contribute to the apparent similarity for a subset of structures. The conformational changes also appear to be independent of the structure determination method, since X-ray crystallographic and cryoEM structures of the SF3b particle are nearly identical (PDB ID 6EN4 vs. 5ZYA, Table 1 ).
Local changes in twist and pitch are focused in a subset of consecutive SF3b1 repeats
Two mechanisms of action could account for the different SF3b1 curvature in the context of the spliceosome compared to the SF3b particle: Small, evenly-distributed changes among the HEAT repeats, or larger, locally-concentrated changes. To investigate these possibilities, we analyzed the twist and pitch relating consecutive SF3b1 repeats ( Fig. 6, Fig. S1 ). The Lightweight Object-Oriented Structure (LOOS) library [33] was used to calculate the angle between the first principal axis and distance between the centroids of consecutive α-helical repeats (representative scripts in Supplementary Material). We maintained a consistent algorithm across a disordered SF3b1 segment in the SF3b particle (residues 1093-1106) by focusing on the C-terminal α-helices of each HEAT repeat (Table S1) , which produced similar results as analyzing dihelical units ( Fig. S1 ). Results also were similar following comparison of the human B ACT with the corresponding structure of the yeast homolog [15] (Fig. S1 ). Table 1 ) following alignment of the C-terminal repeat (residues 1244-1285). (B) View rotated 90°about the x-axis relative to (A). Results are similar following comparison of SF3b1 of the SF3b particle with other spliceosome structures. A movie portraying the conformational transition is given as supplementary information (Supplementary Movie S1).
The average rotational twist relating consecutive helical repeats of the SF3b1 superhelix remains similar between the two states (27 ± 17°i n the SF3b particle and 28 ± 14°in the B ACT spliceosome) ( Fig. 6A ). If uniformly distributed, in principle the one degree difference in twist per repeat could account for the structural change through cumulative addition over the 20 HEAT repeats. However, our analysis instead shows that the different curvature of the two structures arises from significant local changes at a subset of repeats ( Fig. 6B ). Additional overwinding of~10°each is observed at the HEAT repeat steps HR2/ HR3 and HR11/HR12, which respectively interact with the pre-mRNA intron immediately downstream of the BPS, and the endonuclease/ RNaseH-like domains of the core spliceosome protein Prp8. The central HR7/HR8 and HR8/HR9 steps, which contact the RBMX2 and Bud13 subunits of the retention and splicing (RES) complex, also show spliceosome-induced overwinding of~5°each. Remarkably, the insertion of the branch point adenosine in the SF3b1 binding pocket (HR15/ 6 . Relationship between consecutive HEAT repeats of the SF3b1 superhelix in the context of the isolated particle (black, PDB ID 5IFE) or spliceosome (teal, PDB ID 6FF4). The plots analyze the intramolecular step from one HEAT repeat to the next in the indicated superhelix. The steps are numbered on the x-axis for clarity:
Step 1 corresponds to the relationship of HEAT repeat 1 (HR1) to HR2, Step 2 corresponds to the relationship of HR2 to HR3, and so forth. (A) The rotational angle (twist) between the principal axes of a-helices from consecutive HEAT repeats. (B) Bar graph of the differences in the rotational angle of consecutive HEAT repeats between SF3b1 in the two contexts. The average values and standard deviation for the two relatively high resolution human BACT structures (PDB ID's 6FF4 and 5Z58) compared to the SF3b particle are given. Unpaired, two-tailed t-tests with Welch's correction analyze the rotational difference of each repeat relative to the average difference over all repeats: ***, p < .0005; **, p < .005; *, p < .05; not significant, p > .05. Repeats with significant differences are colored teal. (C) Translational shift (pitch) between centroids of a helices from consecutive HEAT repeats. No significant differences in pitch of the superhelix are observed among structures. Results from comparison of the C-terminal a-helix of each di-helical HEAT repeat are shown (residue ranges in Table S1 ), which avoids a disordered region of SF3b1 in the isolated particle (residues 1093-1106). Similar results are obtained from comparison of the intact dihelical units as well as human or yeast homologues (Fig. S1 ). Representative scripts are given as Supplementary Materials. HR16) induces unwinding of the superhelix by −15°, in the opposite direction as other repeats in a manner reminiscent of DNA duplex unwinding by aromatic intercalators [34] . Indeed, the disordered region is near the branch point binding pocket (N-terminal α-helix of HR16, residues 1093-1106) and folds on binding to the BPS -U2 snRNA duplex. Altogether, the overwinding and unwinding of key SF3b1 repeats sums to~20°, consistent with the observed overall~23°change in SF3b1 curvature following integration in the spliceosome.
Clamp-like action of the SF3b1 superhelix
Comparison of the structures reveal that the SF3b1 conformational changes mimic a "clamp" surrounding the BPS -U2 snRNA duplex (Fig. 7A ). The intermolecular distances between the centroids of the dihelix repeats between the aligned structures of human SF3b1 in the SF3b particle (PDB ID: 5IFE) compared to B ACT spliceosome (PDB ID: 6FF4) show a hyperbolic increase at the termini. We explored the dynamics of the SF3b1 protein using an anisotropic network model [35] ( Fig. 7B-C, Supplementary Movies S2-S3 ). The major normal modes close and twist the SF3b1 superhelix analogous to the motion observed for binding to the BPS -U2 snRNA duplex and integration in the spliceosome. This natural flexibility of the SF3b1 protein raises the possibility that the RNA-compatible conformation is selected by the spliceosome from a pre-existing ensemble for the SF3b particle alone, thereby adding to an emerging theme of conformational selection among regulatory proteins [36] . Regardless, the network analysis supports the suitability of the SF3b1 structure to adopt dynamic conformations during spliceosome assembly and disassembly.
Cancer-associated SF3b1 hotspots clustered within the α-helical torus suggest hypotheses for altered splice site choice
Cancer-associated hotspots for acquired SF3b1 mutations cluster in consecutive repeats near the N-terminus of the HEAT domain ( Figs. 2A,  3B) . A K700E substitution accounts for the majority of SF3B1 mutations among hematologic malignancies (e.g. [37] [38] [39] [40] ), including acute myeloid leukemias, chronic myelomonocytic leukemias, chronic lymphocytic leukemias, myelodysplastic syndromes, and refractory anemias with ring sideroblasts, and also recurs in certain pancreatic and breast cancers (e.g. [41] [42] [43] [44] ). Among solid tumors, SF3B1 mutations are most common in uveal melanomas (occurring in 15-20% of patient samples tested) [45] [46] [47] , and the amino acid changes are dominated by R625H/ C or K666 substitutions rather than K700E. The SF3b1 K700, R625, or K666 substitutions promote use of cryptic 3′ splice sites separated by shorter branch point-spliced junction spacings compared to the normal counterparts [48, 49] .
Considering the involvement of the affected SF3b1 residues in intramolecular hydrogen bonds, it was originally proposed that cancerassociated mutations alter splice site choice by changing the specific curvature of the superhelix [14] , which in turn would influence interactions with spliceosome subunits or RNAs and lead to cryptic splice site choice. Subsequently, several spliceosome structures (human PDB ID's: 6QX9, 6AH0, 6AHD, 5Z56, 5Z57, 5Z58; yeast PDB ID's: 5ZWM, 5ZWO, 5LQW, 5GM6) reported interactions between the polypyrimidine splice site signal and the cancer-associated SF3b1 hotspots. Based on these structures, we suggested a possibly interleaved explanation of electrostatic repulsion between the phosphodiester backbone and the prevalent K700E substitution, which could destabilize pre-mRNA contacts, thereby shortening the preferred BPS -splice site spacing of mutant SF3b1 [2] . Yet, network analyses of K700, R625, or K666-mutated SF3b1 models (available on request), and binding of K700E SF3b1 to a strong splice site [14] , lack detectable differences from wild-type, suggesting that additional factors are at play in the biological setting.
Spliceosome inhibitors target the branchsite-binding pocket of SF3b1
SF3b1 is a major target for spliceosome inhibition
Cancer-associated dysregulation highlights the spliceosome as an "Achilles heel" for selective targeting by anti-cancer therapeutics. Nature has taken advantage of this eukaryotic vulnerability and produced small molecule inhibitors of the pre-mRNA splicing pathway (reviewed in [3, 4] ). Remarkably, SF3b1 is the target of the major known class of naturally-occurring spliceosome inhibitors comprising a central conjugated diene separating two variable moieties, including spliceostatin-A precursor from Pseudomonas (sp. 2663) [50] , pladienolides from Streptomyces species [51, 52] , and isoginkgetin isolated from the Metasequoia glyptostroboides dawn redwood tree [53] . Although high-throughput screens have identified other inhibitors of distinct aspects of the pre-mRNA splicing process (reviewed in [54] ), the SF3b1inhibitors remain the most clinically advanced to date. Phase I clinical trials first initiated in 2007 for treatment of solid tumors with a pladienolide-D derivative, E7107 (ClinicalTrials.gov ID: NCT00499499) were suspended due to vision impairment of two participants [55] . More recently, an iteratively optimized derivative starting from a pladienolide scaffold [56] entered Phase I clinical trials for treatment of hematologic malignancies (ClinicalTrials.gov ID: NCT02841540). Knowledge of SF3b1 structures and future characterizations of cancerassociated SF3b1 mutants are likely to aid future optimizations of these promising compounds. 
Inhibitors bind the SF3b1 conformation corresponding to the isolated SF3b particle
Currently, two structures are available of inhibitor-bound SF3b1 in the context of the core human SF3b particle: a co-crystal structure bound to pladienolide-B [57] and a cryoEM structure bound to E7107 [58] . The compounds bind the SF3b1 subunit without significant conformational rearrangement compared to the apo-SF3b particle (respective RMSD 0.2, 1.4, or 1.4 Å between 709, 787, or 795 matching SF3b1 Cα atoms between pairwise alignments of PDB ID's: 5IFE (X-ray, apo) -6EN4 (X-ray, pladienolide B-bound); 5IFE -5ZYA (cryoEM, E7107-bound); 6EN4 -5ZYA, Fig. 8A ). The compound binding site is available only in the "open" conformation of the isolated SF3b particle. A relatively rigid diene group inserts as a molecular wedge between adjacent α-helices of SF3b1 near the BPS-binding site and is enclosed by the PHF5a subunit. Thereby, the bound compound widens the SF3b1 torus, spreading the α-helical repeats a distance incompatible with contacting the RNA duplex. An "hourglass" shape of the inhibitorbinding pocket further explains the ability of this site to accommodate various SF3b1 modulators. The rigid diene is bound within a constricted tunnel between PHF5a and residues near the BPS-binding site of the SF3b1 structure, whereas surrounding openings accommodate the flanking macrocyclic group and aliphatic chain. The locations of residues that confer resistance or sensitivity to pladienolide-based inhibitors [58] [59] [60] , and the structure-activity relationships among different compounds [58, 61, 62] , are structurally consistent. Notably, SF3b1-R1074 and PHF5a-Y36, for which R1074H and Y36C mutations confer resistance to pladienolide derivatives [58, 59] , engage in respective cation-π and π-π interactions with the conjugated diene group. Several residues involved in pladienolide-resistance interact with the branchsite adenosine also form the pladienolide-binding pocket. Altogether, this SF3b-targeted family of spliceosome inhibitors appears to interfere with SF3b1 annealing of the BPS -U2 snRNA strands through a combination of mutually-exclusive interactions and stabilization of the "open" SF3b1 conformation.
Structural implications for spliceosome assembly and therapeutic targeting
Conformational changes in SF3b1 have been proposed to regulate spliceosome assembly and contribute to its cancer-associated defects. An emerging plethora of SF3b1-containing structures open the opportunity to rigorously analyze SF3b1 conformational changes for integration in the spliceosome. The SF3b1 superhelix undergoes significant closure following transition from the isolated SF3b particle to the spliceosome context, enabling the α-helical repeats to surround the BPS -U2 snRNA duplex and shield the branchsite adenosine (Figs. 4-5, Supplementary Movie S1). We find that the dramatic clamp-like action of the SF3b1 torus in the spliceosome arises from large local differences at key regulatory sites. The binding site of the branch point adenosine is locally unwound (opened) analogous to the structural effect of DNA intercalation [34] (Fig. 6 ), which rules out prior proposals that the branch site acts as a wedge driving apart the terminal SF3b1 repeats [14, 57] . Instead, local overwinding at SF3b1 interfaces with the downstream intron and protein subunits more than compensates for the local unwinding at the branch site and accounts for the overall SF3b1 domain closure in the spliceosome. Consistent with the typical malleability of the HEAT repeat fold [63] , network analysis reveals the inherent flexibility of the SF3b1 superhelix and raise the possibility of conformational selection [36] of the spliceosome-associated, "closed" SF3b1 conformation ( Fig. 7) .
Remarkably, the human SF3b1 and yeast Hsh155 structures appear similar among the different spliceosome stages resolved to date. This result is consistent with a major function of SF3b1, stabilization of the BPS -U2 snRNA duplex until release of this RNA duplex for catalytic activation. As such, the similarity of the SF3b1 superhelix conformations among the intermediate pre-B, B, and B ACT spliceosome stages are consistent with an ongoing requirement for SF3b1 to chaperone the BPS -U2 snRNA duplex until the time of catalytic activation. The underlying drivers of the conformational changes during association and release of SF3b1 remains an outstanding topic of investigation. Network analysis suggests that SF3b1 has inherent flexibility ( Fig. 7 , Supplemental Movies S2-S3) and the recombinant SF3b core particle is capable of binding pre-mRNA in vitro [14] . Yet, RNA helicases regulate the entry and exit of SF3b1 from the spliceosome. Several groups have correlated SF3b1/Hsh155 entry in the assembling spliceosome with the RNA helicase Prp5 [28, 29, 31] , although the position of Prp5 has yet to be resolved among spliceosome structures. In later stages, Prp2 has been proposed to release SF3b1 from the B* spliceosome by inducing a change in SF3b1 architecture to a state that is incompatible with the surrounding spliceosomal proteins and RNAs [16, 20, 28, 31] . Accordingly, Prp2 can be visualized bound to the exterior of the SF3b1 torus in most B ACT structures (PDB ID's: 5Z58, 5LQW, 5GM6). However, whether the Prp2 (and Prp5) RNA helicases would directly modulate the SF3b1 protein conformation, as opposed to indirectly influencing access to its RNA binding site, awaits future investigations. The conformational transitions of the SF3b1 superhelix are relevant to understanding the consequences of cancer-associated mutations for therapeutic targeting. One hypothesis is that cancer-associated mutations modify the choice of branch site by favoring an "open" SF3b1 conformation, which in turn influences activation by Prp5 or Prp2 [28, 31] . We have suggested an alternative hypothesis that the mutations disrupt local RNA interactions, thereby shortening the preferred BPS-to-3´splice site spacing [2] . Although these possibilities remain to be experimentally tested, they are likely co-exist and even synergize. For example, an impaired RNA interface with the mutated SF3b1 site would circumvent the ATP-dependent Prp2 checkpoint for certain "weak" splice sites, consistent with the conditional impact of cancerassociated SF3B1 mutations on a subset of spliced junctions [48, 49] . The dynamic SF3b1 conformations provide an important target for drug discovery. Already, the clinically-developed class of pladienolide derivatives exploit the SF3b1 superhelix, rigidifying the "open" SF3b1 conformation and thereby interfering with stable BPS -U2 snRNA association [57, 58] . Future investigations of the structural consequences of SF3b1-targeted mutations and therapies, including contributions of induced fit versus conformational selection, and the detailed interplay of SF3b1 conformations with RNA helicases, will enhance a growing framework for understanding and targeting SF3b1 functions and cancer-associated dysregulation in pre-mRNA splicing.
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